Pascal Deschatelets
CIK 1657720 · Chief Scientific Officer · last filed 2026-05-14
Pascal Deschatelets is a Chief Scientific Officer who has filed 64 SEC Form 4 insider transactions across 1 company since 2018. The most recent filing, for APLS, was dated May 14, 2026. Across all open-market trades the lifetime net is −$32.3M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
64
-$32.32M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Scientific Officer | 0 | $41.03 | $0 | -$32.32M | 64 | 2026-05-14 |
Recent Filings
64 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | −1,222,627 | $0 | EDGAR |
| 2026-01-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +25,840 | $0 | EDGAR |
| 2026-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −5,928 | -$129.0K | EDGAR |
| 2026-01-21 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −909 | -$18.0K | EDGAR |
| 2026-01-15 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,277 | -$50.5K | EDGAR |
| 2025-06-11 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Exer (M) | +12,780 | $48.1K | EDGAR |
| 2025-01-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −826 | -$24.4K | EDGAR |
| 2025-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −3,948 | -$120.1K | EDGAR |
| 2025-01-21 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +14,295 | -$22.5K | EDGAR |